AVITA Medical Plunges 16.29% on Q1 Earnings Miss

On May 9, 2025, AVITA Medical's stock experienced a significant drop of 16.29% in pre-market trading.

AVITA Medical Inc reported its Q1 2025 earnings, revealing an earnings per share (EPS) miss of -$0.53 and revenue that fell short at $18.5 million. This financial performance has raised concerns among investors about the company's short-term prospects.

Despite the disappointing Q1 results, AVITA Medical has outlined a $3.5 billion US market opportunity with its innovative products, such as RECELL GO mini and Cohealyx. These products are expected to drive growth in the coming quarters, providing a potential upside for the company's long-term outlook.

Looking ahead, AVITA Medical has provided financial guidance for the full year of 2025, projecting revenue between $100.00 million and $106.00 million. This guidance is higher than the analyst consensus of $91.45 million, suggesting that the company remains optimistic about its future performance despite the recent setbacks.